All > Vitiligo > Louisiana

INCB054707 for Vitiligo

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
VitiligoINCB054707 - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug to see if it works better than a placebo at treating vitiligo over a 24-week period, followed by a 28-week extension.

Eligible Conditions
  • Vitiligo

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
BBP-398 with nivolumab
1
IO-202
1
Antitumor B

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Up to Week 74

Up to Week 74
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Week 24
Percentage change in Total Vitiligo Area Scoring Index (T-VASI)
Proportion of participants achieving Total Vitiligo Area Scoring Index 50 (T-VASI50)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
BBP-398 with nivolumab
1
IO-202
1
Antitumor B

Side Effects for

INCB054707
30%Upper respiratory tract infection
10%Rash
10%Night sweats
10%Headache
10%Nausea
10%Fibromyalgia
10%Anxiety
This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT03569371) in the INCB054707 ARM group. Side effects include: Upper respiratory tract infection with 30%, Rash with 10%, Night sweats with 10%, Headache with 10%, Nausea with 10%.

Trial Design

4 Treatment Groups

INCB054707 Dose C
1 of 4
INCB054707 Dose B
1 of 4
INCB054707 Dose A followed by Dose C
1 of 4
Placebo followed by INCB054707 Dose C
1 of 4

Experimental Treatment

Non-Treatment Group

171 Total Participants · 4 Treatment Groups

Primary Treatment: INCB054707 · Has Placebo Group · Phase 2

INCB054707 Dose C
Drug
Experimental Group · 1 Intervention: INCB054707 · Intervention Types: Drug
INCB054707 Dose B
Drug
Experimental Group · 1 Intervention: INCB054707 · Intervention Types: Drug
INCB054707 Dose A followed by Dose C
Drug
Experimental Group · 1 Intervention: INCB054707 · Intervention Types: Drug
Placebo followed by INCB054707 Dose C
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INCB054707
2018
Completed Phase 2
~80

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 74

Who is running the clinical trial?

Incyte CorporationLead Sponsor
313 Previous Clinical Trials
46,275 Total Patients Enrolled
6 Trials studying Vitiligo
1,399 Patients Enrolled for Vitiligo

Eligibility Criteria

Age 18 - 75 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a history of prior vitiligo treatment with a total duration of at least 3 months.

Who else is applying?

What state do they live in?
Pennsylvania25.0%
Tennessee25.0%
Arizona25.0%
Other25.0%
How old are they?
18 - 6575.0%
< 1825.0%
What site did they apply to?
Investigative Site 01025.0%
Investigative Site 01525.0%
Investigative Site 02125.0%
Other25.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top